Avere Therapeutics

Avere Therapeutics Secures $2.3 Billion Licensing Deal for Oral IL-23 Inhibitor AVR-001, Reshaping Psoriasis Market Dynamics

Avere Therapeutics has secured a licensing deal with Hansoh Pharma for AVR-001, a long-acting oral IL-23 inhibitor targeting psoriasis and ulcerative colitis, valued at up to $2.3 billion. This move, coupled with a reverse merger and $320 million funding, positions Avere to challenge established injectable and daily oral therapies, potentially reshaping supply chain and procurement strategies for immunology treatments.